BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31865712)

  • 1. Embolotherapy of unresectable hepatocellular carcinoma: Eastern perspective.
    Lu J; Zhong BY; Zhu HD; Guo JH; Teng GJ
    Chin Clin Oncol; 2019 Dec; 8(6):60. PubMed ID: 31865712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concepts in embolotherapy of HCC.
    Pesapane F; Nezami N; Patella F; Geschwind JF
    Med Oncol; 2017 Apr; 34(4):58. PubMed ID: 28299645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
    Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
    Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on Embolization Therapies for Hepatocellular Carcinoma.
    Kishore S; Friedman T; Madoff DC
    Curr Oncol Rep; 2017 Jun; 19(6):40. PubMed ID: 28421483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review.
    Zhao Y; Cai G; Zhou L; Liu L; Qi X; Bai M; Li Y; Fan D; Han G
    Asia Pac J Clin Oncol; 2013 Dec; 9(4):357-64. PubMed ID: 23714021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma.
    Delhaye C; Hendlisz A; Vouche M
    Curr Opin Oncol; 2019 Jul; 31(4):339-345. PubMed ID: 30896451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hepatocellular in the United States.
    Mokdad AA; Hester CA; Singal AG; Yopp AC
    Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.
    Yang B; Zheng B; Yang M; Zeng Z; Yang F; Pu J; Li C; Liao Z
    Hepatol Int; 2018 Sep; 12(5):417-428. PubMed ID: 30073454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC.
    Hou YF; Wei YG; Yang JY; Wen TF; Xu MQ; Yan LN; Li B
    Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):378-85. PubMed ID: 27498577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.